Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Unicycive Therapeutics (Nasdaq: UNCY) announced that CEO Shalabh Gupta, M.D., will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:45 p.m. ET. A live and archived webcast will be available via the company Investor Events and Presentations page.
Positive
- None.
Negative
- None.
News Market Reaction – UNCY
In the Apr 9 session, UNCY gained 3.10%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Earnings & update | Positive | -4.4% | Full-year 2025 results, NDA resubmission acceptance, cash runway into 2027. |
| Feb 04 | Investor conference | Neutral | -5.9% | CEO fireside chat at Guggenheim biotech summit with webcast access. |
| Jan 29 | Regulatory update | Positive | -5.0% | FDA acceptance of OLC NDA resubmission with June 27, 2026 PDUFA date. |
| Dec 29 | NDA resubmission | Positive | -2.3% | Resubmission of OLC NDA, expecting new 1H 2026 PDUFA date guidance. |
| Nov 25 | Investor events | Neutral | +3.6% | Participation in December 2025 investor conferences with webcast availability. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive regulatory and financial updates have often seen negative next-day moves, while routine conference participation has shown more mixed or modestly positive reactions.
Over the past six months, UNCY has focused on advancing oxylanthanum carbonate (OLC) toward potential approval while maintaining conference visibility. Regulatory milestones, including NDA resubmission and FDA acceptance with a June 2026 PDUFA date, and full-year 2025 financials with cash runway into 2027, previously coincided with share price declines. In contrast, prior investor event announcements sometimes saw modest gains. Today’s conference presentation notice fits this pattern of ongoing investor engagement alongside a primarily regulatory-driven story.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Layne Litsinger
Real Chemistry
llitsinger@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
